As of June 3, 2026, AMGN currently lacks a consensus price target and analyst recommendation count, leaving the stock without a defined implied upside within the Healthcare sector. This absence of coverage data stands in contrast to the broader group, which maintains a sector average upside of 20.8%. Investors tracking this name can monitor the Healthcare sector page for updates should analyst reporting resume.
Targets and valuation
The current data profile for AMGN shows no active price target, recommendation tally, or forward P/E metrics. Consequently, there is no quantifiable spread between the market price and analyst expectations. This lack of coverage is notable given the company's status as a large-cap constituent, and the absence of recent price target revisions suggests a period of limited institutional commentary.
Peer comparison
While AMGN remains static in the current dataset, peers continue to show significant implied upside potential:
* DHR: 39.3% upside * ABT: 34.9% upside * TMO: 26.9% upside
These figures highlight a wide variance among sector constituents, with DHR currently leading this group by a considerable margin. Unlike AMGN, these peers possess active consensus models that drive their relative positioning against the 20.8% sector benchmark.